Luminescence-based methods and probes for measuring cytochrome P450 activity

Patent metadata

Field	Value
Publication number	US-9574223-B2
Application number	US-201414319219-A
Country	US
Kind code	B2
Filing date	Jun 30, 2014
Priority date	Sep 20, 2002
Publication date	Feb 21, 2017
Grant date	Feb 21, 2017

Abstract

The invention provides compounds, compositions, methods, substrates, and kits useful for analyzing the metabolic activity in cells, tissue, and animals and for screening test compounds for their effect on cytochrome P450 activity. In particular, a one-step and two-step methods using luminogenic molecules, e.g. luciferins or coelenterazines, that are cytochrome P450 substrates and that are also bioluminescent enzyme, e.g., luciferase, pro-substrates are provided. The present method further provides a method for stabilizing and prolonging the luminescent signal in a luciferase-based assay using luciferase stabilizing agents such as reversible luciferase inhibitors.

First claim

The invention claimed is:

1. A method for determining the effect of a compound on cytochrome P450 enzyme activity in an animal comprising:
(a) administering a test compound to an animal;
(b) administering a luminogenic molecule to the animal, wherein the luminogenic molecule is a cytochrome P450 substrate and a pro-substrate of bioluminescent enzyme;
(c) obtaining a biological sample from said animal;
(d) contacting the biological sample with a reaction mixture comprising a bioluminescent enzyme; and
(e) determining cytochrome P450 enzyme activity of said animal after exposure of said animal to the test compound by measuring and comparing luminescence from said biological sample taken from a second biological sample taken from a second animal not exposed to said test compound;
and wherein the luminogenic molecule is a compound of formula:

wherein
R 1 represents hydrogen, hydroxyl, amino, C 1-20 alkoxy, substituted C 1-20 alkoxy, C 2-20 alkenyloxy, substituted C 2-20 alkenyloxy, halogenated C 2-20 alkoxy, substituted halogenated C 2-20 alkoxy, C 3-20 alkynyloxy, substituted C 3-20 alkynyloxy, C 3-20 cycloalkoxy, substituted C 3-20 cycloalkoxy, C 3-20 cycloalkylamino, substituted C 3-20 cycloalkylamino, C 1-20 alkylamino, substituted C 1-20 alkylamino, di C 1-20 alkylamino, substituted diC 1-20 alkylamino, C 2-20 alkenylamino, substituted C 2-20 alkenylamino, di C 2-20 alkenylamino, substituted di C 2-20 alkenylamino, C 2-20 alkenyl, C 1-20 alkylamino, substituted C 2-20 alkenyl C 1-20 alkylamino C 3-20 alkynylamino, substituted C 3-20 alkynylamino, di C 3-20 alkynylamino, substituted di alkylamino, C 3-20 alkynyl C 2-20 alkenylamino, or substituted C 3-20 alkynyl C 2-20 alkenylamino;
R 2 and R 3 independently represents C or N;
R 4 and R 5 independently represents S, O, NR 8 , wherein R 8 represents hydrogen or C 1-20 alkyl, CR 9 R 10 wherein R 9 and R 10 independently represent H, C 1-20 alkyl, or fluorine;
R 6 represents CH 2 OH; COR 11 wherein R 11 represents H, OH, C 1-20 alkoxide, C 2-20 alkenyl, or NR 12 R 13 wherein R 12 and R 13 are independently H, or C 1-20 alkyl; or —OM + wherein M + is an alkali metal or a pharmaceutically acceptable salt; and
R 7 represent H, C 1-6 alkyl, C 1-20 alkenyl, halogen, or C 1-6 alkoxide,

with the proviso that R 1 is not OH or NH 2 , R 7 is not H, R 6 is not COR 11 R 11 is not OH, R 3 and R 2 are not both carbon, and R 4 and R 5 are not both S at the same time (luciferin and aminoluciferin).

2. The method of claim 1 , wherein step (b) is performed after step (a) after a predetermined time period has elapsed.

3. The method of claim 1 , wherein step (a) and (b) are performed simultaneously.

4. The method of claim 1 , wherein step (b) is performed before step (a).

5. The method of claim 1 , wherein the biological sample comprises tissue, blood; serum, bile, urine, feces, cerebrospinal fluid, lymph, saliva or tears.

6. The method of claim 1 , wherein the bioluminescent enzyme is a luciferase.

7. The method of claim 6 , wherein the luciferase is a beetle luciferase.

8. The method of claim 1 , wherein determining cytochrome P450 enzyme activity after exposure to the test compound comprises in vivo imaging.

9. A method for determining the effect of a compound on cytochrome P450 enzyme activity in a transgenic animal having a bioluminescent enzyme transgene, said method comprising:
(a) administering a test compound to a transgenic animal having a bioluminescent enzyme transgene;
(b) administering a luminogenic molecule to the animal, wherein the luminogenic molecule is a cytochrome P450 substrate and a pro-substrate of the bioluminescent enzyme; and
(c) determining cytochrome P450 enzyme activity of said animal after exposure of said animal to the test compound by measuring and comparing luminescence from tissue from said transgenic animal with a second biological sample taken from a second transgenic animal not exposed to said test compound;
and wherein the luminogenic molecule is a compound of formula:

wherein
R 1 represents hydrogen, hydroxyl, amino, C 1-20 alkoxy, substituted C 1-20 alkoxy, C 2-20 alkenyloxyl, substituted C 2-20 alkenyloxy, halogenated C 2-20 alkoxy, substituted halogenated C 2-20 alkoxy, C 3-20 alkynyloxy, substituted C 3-20 alkynyloxy, C 3-20 cycloalkoxy, substituted C 3-20 cycloalkoxy, C 3-20 cycloalkylamino, substituted C 3-20 cycloalkylamino, C 1-20 alkylamino, substituted C 1-20 alkylamino, di C 1-20 alkylamino, substituted diC 1-20 alkylamino, C 2-20 alkenylamino, substituted C 2-20 alkenylamino, di C 2-20 alkenylamino, substituted di C 2-20 alkenylamino, C 2-20 alkenyl C 1-20 alkylamino, substituted C 2-20 alkenyl C 1-20 alkylamino, C 3-20 alkynylamino, substituted C 3-20 alkynylamino, di C 3-20 alkynylamino, substituted di alkylamino, C 3-20 alkynyl C 2-20 alkenylamino, or substituted C 3-20 alkynyl C 2-20 alkenylamino;
R 2 and R 3 independently represents C or N;
R 4 and R 5 independently represents S, O, NR 8 , wherein R 8 represents hydrogen or C 1-20 alkyl, CR 9 R 10 wherein R 9 and R 10 independently represent H, C 1-20 alkyl, or fluorine;
R 6 represents CH 2 OH; COR 11 wherein R 11 represents H, OH, C 1-20 alkoxide, C 2-20 alkenyl, or NR 12 R 13 wherein R 12 and R 13 are independently H, or C 1-20 alkyl; or —OM + wherein M + is an alkali metal or a pharmaceutically acceptable salt; and
R 7 represent H, C 1-6 alkyl, C 1-20 alkenyl, halogen, or C 1-6 alkoxide,

with the proviso that R 1 is not OH or NH 2 , R 7 is not H, R 6 is not COR 11 R 11 is not OH, R 3 and R 2 are not both carbon, and R 4 and R 5 are not both S at the same time (luciferin and aminoluciferin).

10. The method of claim 9 , wherein step (b) is performed after step (a) after a predetermined time period has elapsed.

11. The method of claim 9 , wherein the bioluminescent enzyme transgene is a luciferase transgene.

12. The method of claim 11 , wherein the luciferase is a beetle luciferase.

13. The method of claim 9 , wherein determining cytochrome P450 enzyme activity of said animal comprises in vivo imaging.

Assignees

• Promega Corp

Inventors

• Cali James J
• Klaubert Dieter
• Daily William
• Ho Samuel Kin Sang
• Frackman Susan
• Hawkins Erika
• Wood Keith V

Classifications

• G01N33/5088

  of vertebrates · CPC title

• C07D417/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• G01N2500/10

  involving cells · CPC title

• G01N2333/90251

  with a definite EC number (1.14.13.-) · CPC title

• G01N2333/90245

  acting on paired donors with incorporation of molecular oxygen (1.14) · CPC title